Patient-reported outcomes with durvalumab, with or without tremelimumab, plus chemotherapy as first-line treatment for metastatic non-small-cell lung cancer (POSEIDON)

By sjmartinez • November 23, 2023

Garon EB, Cho BC, Luft A, Alatorre-Alexander J, Geater SL, Kim SW, Ursol G, Hussein M, Lim FL, Yang CT, Araujo LH, Saito H, Reinmuth N, Medic N, Mann H, Shi X, Peters S, Mok T, Johnson M. Patient-reported outcomes with durvalumab, with or without tremelimumab, plus chemotherapy as first-line treatment for metastatic non-small-cell lung cancer (POSEIDON). Lung Cancer. 2023 Nov 11;186:107422. doi: 10.1016/j.lungcan.2023.107422. Epub ahead of print. PMID: 37992595.

Tags: durvalumab, health-related quality of life, Hematology/Oncology, Metastatic non-small-cell lung cancer, patient-reported outcomes, POSEIDON, Publications, tremelimumab

TROPION-Lung07: Phase III study of Dato-DXd + pembrolizumab ± platinum-based chemotherapy as 1L therapy for advanced non-small-cell lung cancer

Okamoto I, Kuyama S, Girard N, Lu S, Franke F, Li Z, Danchaivijitr P, Han JY, Sun JM, Sugawara S, Pan E, Ren N, Chen[...]

Insurance remains a major source of disparity for patients with testicular cancer: call for advocacy

Starr S, Zhang J, Lin L, Shen J, Gamalong G, Litwin MS, Drakaki A, Chamie K. Insurance remains a major source of disparity for patients[...]

NALIRIFOX in the frontline for metastatic pancreatic cancer: evidence beyond NAPOLI 3

Wainberg ZA, M O'Reilly E. NALIRIFOX in the frontline for metastatic pancreatic cancer: evidence beyond NAPOLI 3. Nat Rev Clin Oncol. 2024 Oct 25. doi: 10.1038/s41571-024-00952-5.[...]